THE APEX TIMES
HCA Healthcare to buy CHCP, betting on education to expand its healthcare workforce pipeline
The Nashville-based hospital operator agreed to acquire ownership of The College of Health Care Professions (CHCP), a Texas allied-health training provider, as it looks to strengthen programs that prepare nurses and other non-physician clinicians.
HCA Healthcare (NYSE: HCA) said it has agreed to acquire ownership of The College of Health Care Professions (CHCP), aiming to expand its in-house ability to train healthcare workers and feed a growing pipeline of staff into its hospitals and other care sites.
In an announcement dated May 27, 2026, HCA said CHCP provides healthcare education to more than 8,000 students annually through 10 campuses in Texas and online. The college, founded in 1988, said it has prepared more than 52,000 students for healthcare careers and emphasizes programs designed for adult learners.
HCA described CHCP as a provider of allied healthcare training, meaning non-physician clinical roles that support patient care, such as medical assisting, imaging and certain technical specialties. CHCP’s offerings include more than 20 accredited programs, including Medical Assisting, Sonography, Surgical Technology, Radiologic Technology, and Medical Coding and Billing. The company also said CHCP offers hybrid, on-campus, and online options intended to let students balance work, family and other responsibilities.
The companies said they have already worked together. HCA said that in 2023 it collaborated with CHCP on a 12-week Medical Assistant training program for colleagues at HCA’s urgent care centers across Texas. HCA reported that since the program launched, more than 100 colleagues have graduated and increased career opportunities within HCA.
Leadership will remain in place at CHCP after the deal. HCA said Eric Bing will continue to lead CHCP as Chancellor and CEO. HCA CEO Sam Hazen said the acquisition is intended to strengthen the “talent pipeline” that serves patients and communities, while Bing said the transaction will carry forward shared goals around adult learner success, academic quality and workforce readiness.
The agreement fits HCA’s broader pattern of investing in nursing and workforce development. HCA said it acquired majority ownership in Galen College of Nursing in 2020, later opening 20 new campuses for a total of 25 campuses nationwide. HCA also said it operates Research College of Nursing in Kansas City, Missouri, and HCA Florida Mercy College of Nursing in Miami, and supported the launch of Pepperdine University’s School of Nursing within the College of Health Sciences in 2025.
The HCA statement added that the company’s foundation has supported education-access initiatives in Texas and Florida, including grants to Educate Texas and the Consortium of Florida Education Foundations intended to increase student access to healthcare career pathways.
HCA did not disclose the transaction terms, price, expected timeline, or the anticipated timing for regulatory approval. The company said the acquisition is subject to regulatory approval and customary closing conditions. With those details still unavailable, it is unclear how CHCP’s program mix, campus footprint, or integration into HCA’s broader education strategy may change before or after closing.
Why It Matters
- The acquisition indicates HCA’s effort to address workforce bottlenecks by building training capacity rather than relying only on external hiring.
- By adding an allied-health education platform alongside its nursing education investments, HCA is broadening its strategy beyond nursing into multiple technician and support roles.
- For students and employers, the deal could reshape career pathways by potentially expanding clinical training and placement opportunities tied to HCA facilities.
- Regulatory approval and deal integration are key uncertainties, especially given that HCA did not disclose financial terms or a closing timeframe.
Sources
Key Facts
- HCA Healthcare agreed to acquire ownership of The College of Health Care Professions (CHCP).
- CHCP said it educates more than 8,000 students annually across 10 Texas campuses and online.
- HCA said CHCP has prepared more than 52,000 students since opening in 1988 and offers more than 20 accredited programs.
- HCA reported that a 2023 CHCP collaboration, a 12-week Medical Assistant training program for HCA urgent care staff in Texas, produced more than 100 graduates.
- Eric Bing will continue to lead CHCP as Chancellor and CEO after the acquisition.
- HCA said the deal is subject to regulatory approval and customary closing conditions, and it did not disclose transaction terms.
Healthcare Related
Bristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debate
A market analysis comparing Bristol-Myers Squibb and Johnson & Johnson in 2026 points to a valuation gap, while warning that BMY’s financial leverage and patent risks could outweigh its cheaper price. JNJ’s case rests on its diversified business model.
Moderna Shares Slip as Biotech Pullback Spurs Caution, Investors Told Not to Overreact
A market-wide retreat in biotech stocks is weighing on Moderna, but analysts cited upcoming company and partner catalysts that could help stabilize sentiment.
Pfizer set to report Q3 2026 earnings next month, with analysts bracing for profit decline
Ahead of Pfizer’s third-quarter 2026 results, market watchers are preparing for a double-digit dip in profit, underscoring how sensitive the company’s earnings outlook remains to new-product growth and shifting demand.
Pfizer extends dividend streak to 352 straight quarters, but questions linger on sustainability
Pfizer announced another quarterly payout, marking a long run of uninterrupted dividends. A key debate for investors is whether the current yield can be maintained as the company navigates patent cliffs, pipeline execution, and generics competition.
Eli Lilly bulls shift focus from Zepbound to pipeline, arguing newer drugs could drive the next growth cycle
A recent market commentary from Yahoo Finance urged investors to look past Zepbound and toward Eli Lilly’s broader drug discovery engine, citing three newer medicines as potential drivers.
A $1,000 Bet on Eli Lilly Turned Into $18,637, Highlighting How One Obesity Drug Reshaped the Market
A recent market-focused analysis argues that Eli Lilly’s transition from an insulin-dominant history to obesity blockbuster status transformed not just the company, but also how investors think about the category.
Q2 hospital-chain stock spotlight: Yahoo Finance compares HCA Healthcare with peers as earnings season ends
A new Yahoo Finance wrap-up looks across hospital operators to identify which hospital-chain stocks stood out and which lagged during the latest quarterly earnings cycle, placing HCA Healthcare in the peer set.
Johnson & Johnson outlines a growth reset as pharma strength offsets sluggish MedTech
A recent market-focused review points to uneven performance across Johnson & Johnson’s businesses, with pharmaceutical momentum helping compensate for stalled MedTech growth, alongside a strategy built around new product launches and a planned spin-off.
Pfizer’s discount to AbbVie is widening the valuation question in pharma’s core medicines
A Yahoo Finance comparison highlights how Pfizer’s lower share price has investors weighing whether the market is pricing in real fundamental risk or simply valuing different mixes of profitable drugs.
UnitedHealth Q3 margins improved, but shrinking membership puts pressure on the growth narrative
A reported jump in profit margins came alongside falling membership in UnitedHealth’s latest quarter, reviving questions about how durable the company’s operating turnaround will be.
